Hepatitis B Virus X Protein Modulates Chemokine CCL15 Upregulation in Hepatocellular Carcinoma.

Hepatitis B Virus X Protein Modulates Chemokine CCL15 Upregulation in Hepatocellular Carcinoma.
复制标题

DOI:
10.2174/1871520621666210302083407
复制
发表时间:
2021-03
影响因子:
2.8
通讯作者:
Ying Li;Chaomin Wang;Ting Zhao;R. Cui;Linfei Hu;Luchen Chang;Xi Wei;Jin Zhang;Yueguo Li
Ying Li;Chaomin Wang;Ting Zhao;R. Cui;Linfei Hu;Luchen Chang;Xi Wei;Jin Zhang;Yueguo Li
中科院分区:
医学4区
文献类型:
--
作者:
Ying Li;Chaomin Wang;Ting Zhao;R. Cui;Linfei Hu;Luchen Chang;Xi Wei;Jin Zhang;Yueguo Li

文献摘要

相似文献

背景:B型肝炎病毒X蛋白(HBx)是肝细胞癌(HCC)不可或缺的进展因子。CCL15可能是HCC发生和侵袭的特异性蛋白质组标志物。目的探讨肝细胞癌组织中HBx和CCL15表达的关系。方法明确收集HBV阳性的HCC病理组织标本及相应的癌旁非肿瘤肝组织标本。采用免疫组化、实时荧光定量PCR和Western blot方法检测肝组织和体外培养肝组织中HBx和CCL15的表达。结果肝癌组织中CCL15 mRNA和蛋白的表达水平明显高于癌旁肝组织。CCL15与HBV阳性HCC标本中HBx的表达显著相关。HBx的上调在体外诱导CCL 15的表达。CCL15的高表达与HCC患者的不良预后显著相关。结论:HCC患者中CCL15的表达与HBx密切相关。CCL15可作为HBV相关性HCC临床治疗的一个指标。
BACKGROUND Hepatitis B virus X protein (HBx) is an indispensable progression factor in hepatocellular carcinoma (HCC). CCL15 could be a peculiar proteomic biomarker of HCC with tumorigenesis and tumor invasion. OBJECTIVE The aim of study was to explore the relationship between HBx and CCL15 expression in HCC. METHODS HBV-positive HCC pathological tissue samples and corresponding adjacent non-tumor liver tissues were clearly collected. The expression of HBx and CCL15 was analyzed by immunohistochemistry, real-time polymerase chain reaction (PCR) and western blot analysis in tissues or in vitro. RESULTS The levels of CCL15 mRNA and protein expression in HCC samples were observably higher than the ones of adjacent non-tumor liver tissues. The CCL15 was significantly associated with the expression of HBx in HBV-positive HCC samples. The up-regulation of HBx induced CCL15 expression in vitro. The high expression score of CCL15 was significant associated with the poor prognosis of HCC patients. CONCLUSIONS The CCL15 expression was observably associated with HBx in HCC patients. The CCL15 may be considered as a indicator in clinical managment of HBV-associated HCC.